101. An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities
- Author
-
Ari Melnick, Sanil Bhatia, Janine Altmüller, Arina Riabinska, Tim Rehkämper, Julia Hauer, Andreas R. Klatt, Sebastian Klein, Gero Knittel, Marcus Krüger, Ilmars Kisis, Pauline Pfeiffer, Anthony Letai, Arndt Borkhardt, Wendy Béguelin, Clemens A. Schmitt, Ruth Flümann, Laura Pasqualucci, Hans Christian Reinhardt, Pascal Nieper, Janica L Wiederstein, Sandrine Sander, Alessandra Holzem, Alexandra da Palma Guerreiro, Anna Brunn, Philipp Lohneis, Reinhard Büttner, Maurice Reimann, Martina Deckert, Benedikt W. Pelzer, Hamid Kashkar, Martin Peifer, Manuel Montesinos-Rongen, Heinz Ahlert, Lukas P. Frenzel, Thorsten Persigehl, Moritz Kochanek, and Jeremy Ryan
- Subjects
Medizin ,Biology ,Article ,Mice ,chemistry.chemical_compound ,immune system diseases ,In vivo ,hemic and lymphatic diseases ,Gene expression ,medicine ,Animals ,neoplasms ,Exome sequencing ,Venetoclax ,Germinal center ,General Medicine ,Germinal Center ,medicine.disease ,Genes, bcl-2 ,Lymphoma ,Proto-Oncogene Proteins c-bcl-2 ,chemistry ,Cell culture ,Myeloid Differentiation Factor 88 ,Cancer research ,Lymphoma, Large B-Cell, Diffuse ,Diffuse large B-cell lymphoma - Abstract
Based on gene expression profiles, diffuse large B-cell lymphoma (DLBCL) is subdivided into germinal center B-cell–like (GCB) and activated B-cell–like (ABC) DLBCL. Two of the most common genomic aberrations in ABC-DLBCL are mutations in MYD88 as well as BCL2 copy-number gains. Here, we employ immune phenotyping, RNA sequencing, and whole-exome sequencing to characterize a Myd88- and BCL2-driven mouse model of ABC-DLBCL. We show that this model resembles features of human ABC-DLBCL. We further demonstrate an actionable dependence of our murine ABC-DLBCL model on BCL2. This BCL2 dependence was also detectable in human ABC-DLBCL cell lines. Moreover, human ABC-DLBCLs displayed increased PD-L1 expression compared with GCB-DLBCL. In vivo experiments in our ABC-DLBCL model showed that combined venetoclax and PD-1 blockade significantly increased the overall survival of lymphoma-bearing animals, indicating that this combination may be a viable option for selected human ABC-DLBCL cases harboring MYD88 and BCL2 aberrations. Significance: Oncogenic Myd88 and BCL2 cooperate in murine DLBCL lymphomagenesis. The resulting lymphomas display morphologic and transcriptomic features reminiscent of human ABC-DLBCL. Data derived from our Myd88/BCL2-driven autochthonous model demonstrate that combined BCL2 and PD-1 blockade displays substantial preclinical antilymphoma activity, providing preclinical proof-of-concept data, which pave the way for clinical translation. This article is highlighted in the In This Issue feature, p. 1
- Published
- 2021
- Full Text
- View/download PDF